Antagonism of N-methyl-D-aspartate receptors reduces the vulnerability of the immune system to stress after chronic morphine

被引:4
作者
Alonzo, NC
Bayer, BM
机构
[1] Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA
[2] Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA
关键词
D O I
10.1124/jpet.103.053264
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been shown that morphine-tolerant animals have an altered immunological sensitivity to stress. Although the glutamatergic system has been implicated in the neuroadaptive process underlying this tolerant state, its potential role in development of the altered immunological sensitivity consequent to chronic morphine treatment is not known. To determine this, a morphine-tolerant state was induced by 10-day administration of an escalating dose of morphine from 10 to 40 mg/kg (s. c., b. i. d.), and lymphocyte proliferative response to a T-cell mitogen was measured. Morphine challenge (10 mg/kg s.c.) after days of treatment was gradually less immunosuppressive, and this tolerance progression was delayed by concurrent administration of the N-methyl-D-aspartate (NMDA) receptor antagonist (-)- 5-methyl- 10,11-dihydro-5H-dibenzo[a, d] cyclohepten-5,10-imine maleate (MK-801) (0.1 mg/kg s.c.) with chronic morphine. The effect was independent of glucocorticoid level changes and was not a result of an acute interaction of the drugs or the prolonged presence of the antagonist alone. Subsequent to chronic treatment, animals were subjected to opioid withdrawal and water stress. Both stressors induced 50% immunosuppression in morphine-tolerant animals compared with saline-treated controls. Increased immunological sensitivity to these stressors was attenuated when MK-801 was administered with chronic morphine as demonstrated by an accelerated recovery rate and lack of immunosuppression from opioid withdrawal and water stress, respectively. Together, these findings provide the first evidence that the neuroadapted state of the immune response after chronic morphine can be modified by NMDA receptor antagonism, as illustrated by a temporal deceleration of the development of immunological tolerance during chronic treatment that is associated with an attenuation of the immunological vulnerability of morphine-tolerant animals to stress.
引用
收藏
页码:793 / 800
页数:8
相关论文
共 75 条
[21]   Attenuation of precipitated morphine withdrawal symptoms by acute icv administration of a group IImGluR agonist [J].
Fundytus, ME ;
Coderre, TJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (03) :511-514
[22]   Glutamate receptors and nociception - Implications for the drug treatment of pain [J].
Fundytus, ME .
CNS DRUGS, 2001, 15 (01) :29-58
[23]   Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists [J].
Gonzalez, P ;
Cabello, P ;
Germany, A ;
Norris, B ;
Contreras, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 332 (03) :257-262
[24]   Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels [J].
González, S ;
Fernández-Ruiz, J ;
Sparpaglione, V ;
Parolaro, D ;
Ramos, JA .
DRUG AND ALCOHOL DEPENDENCE, 2002, 66 (01) :77-84
[25]  
HERMAN BH, 1995, NEUROPSYCHOPHARMACOL, V13, P269, DOI 10.1016/0893-133X(95)00140-9
[26]  
HERNANDEZ MC, 1993, J PHARMACOL EXP THER, V267, P1336
[27]   Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: A chronic stress paradigm [J].
Houshyar, H ;
Cooper, ZD ;
Woods, JH .
JOURNAL OF NEUROENDOCRINOLOGY, 2001, 13 (10) :862-874
[28]   Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: Possible mechanisms involved in facilitated and attenuated stress responses [J].
Houshyar, H ;
Galigniana, MD ;
Pratt, WB ;
Woods, JH .
JOURNAL OF NEUROENDOCRINOLOGY, 2001, 13 (10) :875-886
[29]   EFFECT OF CHRONIC MORPHINE ON THE RESPONSE TO AND DISPOSITION OF OTHER DRUGS [J].
HOWD, RA ;
PRYOR, GT .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1980, 12 (04) :577-586
[30]  
IGNAR DM, 1990, J PHARMACOL EXP THER, V255, P1287